Individualized Administration of Warfarin by Polymorphisms of VKORC1 and CYP2C9 Genes
NCT03797534 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2019-01-15
Summary
The purpose of this study is to explore the individualized administration model of warfarin suitable for Chinese people, and provide a scientific reference for the use of warfarin to Chinese people.
Conditions
- Heart Valve Prosthesis
Interventions
- OTHER
-
dose regime
The initial dose of the experimental group will be calculated by the Bayesian model.
Sponsors & Collaborators
-
Fujian Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-02-01
- Primary Completion
- 2022-01-01
- Completion
- 2023-01-01
Countries
- China
Study Locations
More Related Trials
-
The Study of Warfarin Maintenance Dose in Chinese Patients
NCT01855737 ·Status: UNKNOWN
-
Pharmacogenetic Dosing of Warfarin
NCT02065388 ·Status: COMPLETED ·Phase: PHASE3
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN
-
Genotype-guided Warfarin Individualized Treatment
NCT02211326 ·Status: COMPLETED ·Phase: NA
-
Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)
NCT00634907 ·Status: COMPLETED ·Phase: NA
-
Genetic Determinants of Warfarin Anticoagulation Effect
NCT00162435 ·Status: UNKNOWN ·Phase: NA
-
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose
NCT00700895 ·Status: UNKNOWN ·Phase: PHASE3
-
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464 ·Status: COMPLETED ·Phase: NA
-
Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis
NCT02240953 ·Status: UNKNOWN ·Phase: NA
-
Gene-guided Warfarin for Anticoagulation Therapy
NCT04482842 ·Status: WITHDRAWN ·Phase: NA
-
EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin
NCT01119300 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population
NCT01050920 ·Status: UNKNOWN
-
Warfarin Dosage Adjustment Model Analysis Study
NCT05609500 ·Status: UNKNOWN
-
Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity
NCT02069132 ·Status: UNKNOWN
-
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
NCT03885180 ·Status: UNKNOWN ·Phase: NA
-
Early Identification of Warfarin Maintenance Dosage
NCT01178034 ·Status: COMPLETED ·Phase: PHASE3
-
The Prevalence of Sub Optimal Anti Coagulation
NCT03485300 ·Status: UNKNOWN
-
Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
NCT00356759 ·Status: COMPLETED ·Phase: PHASE2
-
Safer Warfarin Treatment
NCT01042067 ·Status: SUSPENDED
-
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
NCT00806624 ·Status: COMPLETED ·Phase: PHASE2
-
Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR
NCT05375474 ·Status: RECRUITING ·Phase: PHASE4
-
Genetic Response to Warfarin in Healthy Subjects
NCT01520402 ·Status: COMPLETED ·Phase: NA
-
A Prospective Cohort Study on Warfarin Personalized Medication
NCT06428110 ·Status: COMPLETED
-
Dabigatran Versus Warfarin With NVAF Who Undergo PCI
NCT03536611 ·Status: UNKNOWN ·Phase: PHASE4